Article
Biochemistry & Molecular Biology
Anna Kirstein, Daniela Schilling, Stephanie E. Combs, Thomas E. Schmid
Summary: The study shows that Lomeguatrib can inhibit MGMT protein and sensitize cells to radiation therapy. Low concentrations of Lomeguatrib have a radiosensitizing effect, while high concentrations have a radioprotective effect.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Oncology
Martin Glas, Matthew T. Ballo, Ze'ev Bomzon, Noa Urman, Shay Levi, Gitit Lavy-Shahaf, Suriya Jeyapalan, Terence T. Sio, Paul M. DeRose, Martin Misch, Sophie Taillibert, Zvi Ram, Andreas F. Hottinger, Jacob Easaw, Chae-Yong Kim, Suyash Mohan, Roger Stupp
Summary: TTFields treatment affects the rate of distant progression in newly diagnosed GBM patients, with distant lesions appearing further from the primary lesion in the TTFields treatment arm. Distant progression correlates with improved clinical outcomes in TTFields patients.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
(2022)
Review
Oncology
Xanthene Miles, Charlot Vandevoorde, Alistair Hunter, Julie Bolcaen
Summary: Inhibition of the MDM2/X-p53 interaction as a potential anti-cancer strategy, especially in treating GB, by reactivating p53 plays a central role in cell survival and cancer therapy effectiveness. Suppression of MDM2 presents an opportunity for new therapeutic interventions for GB, with combination with radiation showing promise as a valuable treatment approach.
FRONTIERS IN ONCOLOGY
(2021)
Article
Chemistry, Multidisciplinary
Ke Wang, Abduladheem Turki Jalil, Marwan Mahmood Saleh, Sona Talaei, Linlin Wang
Summary: In this study, a targeted nanoradiosensitizer was developed for the treatment of Glioblastoma tumor. The nanoparticles showed high chemical stability, non-toxicity, and biodegradability, with bismuth sulfide as the radiosensitizer agent coated with bovine serum albumin. Glutathione was employed as the BBB shuttle peptide. The results of the study demonstrated significant efficacy of the treatment on cancer cell lines.
Article
Chemistry, Multidisciplinary
Maoyuan Sun, Honglei Xie, Wenli Zhang, Xianlu Li, Zhan Jiang, Yiyu Liang, Guanjian Zhao, Ning Huang, Jinning Mao, Guodong Liu, Zhiwen Zhang
Summary: A bioinspired lipoprotein system based on CCL5 is designed to target GBM and overcome radiotherapy resistance by releasing gemcitabine and NO.
Article
Engineering, Environmental
Meijuan He, Tingting Xiao, Yihui Wang, Hongwei Yu, Zilin Wang, Xiangyang Shi, Han Wang
Summary: In this study, we developed an immunostimulated nanoplatform for MRI-guided radiotherapy against GBM. The platform effectively enhances the immune response and shows promising therapeutic efficacy.
CHEMICAL ENGINEERING JOURNAL
(2023)
Article
Oncology
Ziwei Tu, Huifen Xiong, Yang Qiu, Guoqing Li, Li Wang, Shiyi Peng
Summary: The study aimed to determine the optimal treatment volume for GBM by measuring the distances between recurring tumors and primary lesions. Factors influencing recurrence were identified, with 1cm margin covering 94.8% of local recurrences, providing important guidance for accurate treatment of GBM patients.
Article
Oncology
Nalee Kim, Jongyo Lee, Do-Hyun Nam, Jung-Il Lee, Ho Jun Seol, Doo-Sik Kong, Jung Won Choi, Kyuha Chong, Won Jae Lee, Jong Hee Chang, Seok-Gu Kang, Ju Hyung Moon, Jaeho Cho, Do Hoon Lim, Hong In Yoon
Summary: There is no significant difference in overall survival (OS) between sequential boost (SEB) and simultaneous integrated boost (SIB) techniques for glioblastoma multiforme (GBM) patients treated with concurrent chemoradiotherapy (CCRT).
JOURNAL OF NEURO-ONCOLOGY
(2023)
Article
Biochemistry & Molecular Biology
Pawel Kochanowski, Jessica Catapano, Maciej Pudelek, Tomasz Wrobel, Zbigniew Madeja, Damian Ryszawy, Jaroslaw Czyz
Summary: GBM recurrences after TMZ treatment are caused by drug-resistant and invasive cells, with MGMT playing a key role. Different cell populations respond differently to long-term TMZ stress, with mechanisms involving Snail-1, Cx43, and MGMT activity. High MGMT remains essential for the microevolution of GBM invasiveness under long-term TMZ stress.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Review
Biochemistry & Molecular Biology
Rosa Della Monica, Mariella Cuomo, Michela Buonaiuto, Davide Costabile, Raduan Ahmed Franca, Marialaura del Basso De Caro, Giuseppe Catapano, Lorenzo Chiariotti, Roberta Visconti
Summary: Epigenetic changes in DNA methylation, especially in the MGMT gene, can serve as biomarkers for predicting response to therapy and prognosis in glioblastoma. Whole-genome DNA methylation analysis has improved the classification of glioblastomas. DNA methylation changes, particularly in glioblastomas with IDH1/2 mutations, can be targeted for tailored therapy.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Pharmacology & Pharmacy
Jigang Chen, Xin Tong, Mingyang Han, Songfeng Zhao, Linjin Ji, Yongkai Qin, Zilong He, Yuesong Pan, Chunhui Wang, Aihua Liu
Summary: The study found that RT plus TMZ treatment for elderly GBM patients in the US is associated with higher costs, but offers greater long-term survival and quality of life benefits. However, in China, this treatment strategy is not cost-effective and requires a decrease in the price of TMZ.
FRONTIERS IN PHARMACOLOGY
(2021)
Article
Cell Biology
Alessandro Tancredi, Olga Gusyatiner, Pierre Bady, Michelle C. Buri, Remy Lomazzi, Davide Chiesi, Mahmoud Messerer, Monika E. Hegi
Summary: Bromodomain and extra-terminal tail (BET) proteins are potential epigenetic targets in cancer, including glioblastoma. BET inhibitors disrupt the histone code-gene transcription link. BET-induced differential gene expression in glioblastoma derived-spheres revealed 6 distinct response patterns. The O-6-methylguanine-DNA methyltransferase (MGMT) gene, a known resistance factor for glioblastoma treatment, showed consistent downregulation in response to BET inhibitors.
CELL DEATH & DISEASE
(2022)
Article
Biochemistry & Molecular Biology
Vasiliki Zoi, Vasiliki Galani, Pericles Tsekeris, Athanasios P. Kyritsis, George A. Alexiou
Summary: Radiation therapy is important in cancer treatment, but radiation toxicity limits its efficacy. Curcumin has significant anti-tumor properties and can sensitize cancer cells to radiation while being safe for healthy cells. This review summarizes the role of curcumin as both a radiosensitizer and radioprotector based on recent experimental and clinical evaluations.
Article
Nanoscience & Nanotechnology
Song Yang, Gaohua Han, Quan Chen, Lei Yu, Peng Wang, Qi Zhang, Jiang Dong, Wei Zhang, Junxing Huang
Summary: The study designed PEG-functionalized nanoparticles to increase radiosensitivity and found that AuPt NPs exhibit enzyme-like activity by promoting the decomposition of H2O2 in the tumor microenvironment. The results demonstrate that this approach can enhance the efficacy of radiotherapy.
INTERNATIONAL JOURNAL OF NANOMEDICINE
(2021)
Article
Biochemistry & Molecular Biology
Zahra Habibi-Kelishomi, Bahram Goliaei, Alireza Nikoofar
Summary: Butein, a polyphenolic compound of flavonoids family, exhibits anti-cancer properties and enhances the radiosensitivity of cancer cells. Studies have shown that butein treatment can reduce radiation-induced G2/M cell cycle arrest, increase DNA damage, promote apoptosis, and decrease colony-forming ability of irradiated cells.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
(2021)
Article
Oncology
Stefano Molica, Diana Giannarelli, Mirella Lentini, Daniela Zappala, Ada Mannella, Daniela Loiacono, Valentina Gianfelici, Giuseppina Panduri, Iris Gariani, Pasquale Minchella, Francesco Talarico, Luciano Levato
Summary: The antibody response to the BNT162b2 mRNA COVID-19 vaccine in CLL patients is impaired, with the highest response rate observed in treatment-naive patients and those in sustained clinical remission after therapy. However, CLL patients on certain treatments are less likely to respond well to the vaccine.
Article
Oncology
Alba Di Leone, Antonio Franco, Daniela Andreina Terribile, Stefano Magno, Alessandra Fabi, Alejandro Martin Sanchez, Sabatino D'Archi, Lorenzo Scardina, Maria Natale, Elena Jane Mason, Federica Murando, Fabio Marazzi, Armando Orlandi, Ida Paris, Giuseppe Visconti, Antonella Palazzo, Valeria Masiello, Liliana Barone Adesi, Marzia Salgarello, Riccardo Masetti, Gianluca Franceschini
Summary: In patients with breast cancers larger than 2 cm undergoing neoadjuvant chemotherapy, oncoplastic surgery level II (OPSII) and mastectomy with immediate breast reconstruction (MIBR) have been compared for their aesthetic and oncological outcomes. The study confirmed that OPSII is a safe alternative to MIBR, as it provides similar loco-regional and systemic disease-free survival and overall survival rates. OPSII also results in a lower loss of breast sensitivity and better physical well-being compared to MIBR.
Review
Medicine, General & Internal
Luca Mastrantoni, Armando Orlandi, Antonella Palazzo, Giovanna Garufi, Alessandra Fabi, Gennaro Daniele, Diana Giannarelli, Giampaolo Tortora, Emilio Bria
Summary: This systematic review and meta-analysis examined the use of CDK4/6 inhibitors in hormone-receptor positive/HER2-negative metastatic breast cancer. The study found that CDK4/6 inhibitors had a significant benefit in terms of progression-free survival compared to placebo. In terms of adverse events, different CDK4/6 inhibitors had varying advantages and disadvantages. The study confirmed the reliability of LHH as a tool for balancing the risks and benefits of experimental drugs.
Article
Medicine, General & Internal
Silvia Salvatori, Irene Marafini, Martina Franchin, Diletta Lavigna, Mattia Brigida, Chiara Venuto, Livia Biancone, Emma Calabrese, Diana Giannarelli, Giovanni Monteleone
Summary: It has been reported that frailty status can have a negative impact on the clinical progress of patients with inflammatory bowel diseases (IBDs). A recent study found that 20% of IBD patients are frail, and disease activity increases the risk of frailty. The study prospectively monitored a subgroup of frail patients, assessed the reversibility of frailty status, and analyzed factors associated with its reversibility. Results showed that frail phenotype is reversible in most IBD patients, with improvement in disease activity playing a significant role.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Oncology
Giuditta Chiloiro, Angela Romano, Silvia Mariani, Gabriella Macchia, Diana Giannarelli, Luciana Caravatta, Pierfrancesco Franco, Luca Boldrini, Alessandra Arcelli, Almalina Bacigalupo, Liliana Belgioia, Antonella Fontana, Elisa Meldolesi, Giampaolo Montesi, Rita Marina Niespolo, Elisa Palazzari, Cristina Piva, Vincenzo Valentini, Maria Antonietta Gambacorta
Summary: This study aims to evaluate the role of baseline inflammatory markers as prognostic and predictive factors in a large multicentric Italian cohort of locally advanced rectal cancer patients. The study found that a neutrophil-to-lymphocyte ratio (NLR) >1.2 and a systemic index of inflammation (SII) >500 could predict pathological complete response (pCR). In addition, monocyte-to-lymphocyte ratio (MLR) and hemo-eosinophils inflammation index (HEI) were also associated with disease-free survival (DFS), and age, MLR, and HEI were independent predictors of overall survival (OS).
CLINICAL AND TRANSLATIONAL RADIATION ONCOLOGY
(2023)
Review
Oncology
Inge T. A. Peters, Claudia Marchetti, Antonella De Palma, Diana Giannarelli, Antonella Carcagni, Giovanni Scambia, Anna Fagotti
Summary: First-line maintenance therapy with PARPi significantly improves PFS in patients with advanced high-grade serous and endometrioid EOC. However, the effect of PARPi in relation to postoperative residual disease status is still lacking.
EUROPEAN JOURNAL OF CANCER
(2023)
Article
Oncology
Stefania Gori, Alessandra Fabi, Catia Angiolini, Monica Turazza, Piermario Salvini, Gianluigi Ferretti, Elisabetta Cretella, Lorenzo Gianni, Claudia Bighin, Angela Toss, Claudio Zamagni, Patrizia Vici, Costanza De Rossi, Antonio Russo, Giancarlo Bisagni, Antonio Frassoldati, Lucia Borgato, Anna Cariello, Claudia Cappelletti, Roberto Bordonaro, Saverio Cinieri, Alessandra Modena, Matteo Valerio, Maria Francesca Alvisi, Irene De Simone, Francesca Galli, Eliana Rulli, Anna Santoni, Fabrizio Nicolis
Summary: This study evaluated the rate of early breast cancer patients treated with neoadjuvant systemic therapy in Italy. It found that 13.9% of patients received this treatment. Various factors such as menopausal status, tumor size, lymph node involvement, grade, HER2 status, and triple negative subtype were associated with the decision to administer neoadjuvant therapy. The choice of therapy also varied based on the patient's phenotype subgroup.
Article
Oncology
Alessandra Fabi, Luisa Carbognin, Andrea Botticelli, Ida Paris, Paolo Fuso, Maria Cristina Savastano, Nicla La Verde, Carla Strina, Rebecca Pedersini, Stefania Guarino, Giuseppe Curigliano, Carmen Criscitiello, Mimma Raffaele, Alessandra Beano, Antonio Franco, Maria Rosaria Valerio, Francesco Verderame, Andrea Fontana, Eva Regina Haspinger, Alessia Caldara, Alba Di Leone, Giampaolo Tortora, Diana Giannarelli, Giovanni Scambia
Summary: The ANASTASE study retrospectively analyzed data from PD-L1-positive mTNBC patients treated with atezolizumab plus nab-paclitaxel and found similar results in terms of PFS and ORR as reported in the IMpassion130 study, with no unexpected adverse events.
Article
Health Care Sciences & Services
Antonio Franco, Alba Di Leone, Marco Conti, Alessandra Fabi, Luisa Carbognin, Andreina Daniela Terribile, Paolo Belli, Armando Orlandi, Martin Alejandro Sanchez, Francesca Moschella, Elena Jane Mason, Giovanni Cimino, Alessandra De Filippis, Fabio Marazzi, Ida Paris, Giuseppe Visconti, Liliana Barone Adesi, Lorenzo Scardina, Sabatino D'Archi, Marzia Salgarello, Diana Giannarelli, Riccardo Masetti, Gianluca Franceschini, Kenneth P. H. Pritzker
Summary: This study developed a post-Neoadjuvant Score System (pNESSy) to choose the appropriate surgery and improve oncological and aesthetic outcomes. The system uses clinical and radiological features to predict the optimal surgery method post-neoadjuvant chemotherapy.
JOURNAL OF PERSONALIZED MEDICINE
(2023)
Article
Oncology
Fabrizio Nelli, Agnese Fabbri, Antonella Virtuoso, Diana Giannarelli, Julio Rodrigo Giron Berrios, Eleonora Marrucci, Cristina Fiore, Marta Schirripa, Carlo Signorelli, Mario Giovanni Chilelli, Francesca Primi, Gloria Pessina, Federica Natoni, Maria Assunta Silvestri, Enzo Maria Ruggeri
Summary: Clinical implications of COVID-19 outbreaks following vaccination in immunocompromised cancer patients were studied. The study found a correlation between antibody levels and the development of breakthrough infections as well as cancer treatment failure. Strategies to enhance antibody levels and prevent virus transmission should be prioritized to mitigate the impact on disease outcomes.
Article
Oncology
Sara Socorro Faria, Diana Giannarelli, Vladmir Claudio Cordeiro de Lima, Sumadi Luckman Anwar, Chiara Casadei, Ugo De Giorgi, Gabriele Madonna, Paolo Antonio Ascierto, Rossana Veronica Mendoza Lopez, Roger Chammas, Mariaelena Capone
Summary: Breast cancer-related inflammation plays a critical role in tumor development, cancer progression, and patient prognosis. In this study, a prognostic model was established and validated to predict disease-free survival in early-stage breast cancer patients based on readily available baseline clinicopathological prognostic factors and preoperative blood count-derived lymphocyte ratios.
Article
Oncology
Nicolo Bizzarri, Majdi Imterat, Robert Fruscio, Diana Giannarelli, Anna Myriam Perrone, Rosanna Mancari, Alexander Traut, Andrea Rosati, Andreas du Bois, Debora Ferrari, Pierandrea De Iaco, Raffaella Ergasti, Beyhan Ataseven, Tommaso Bianchi, Marco Di Stanislao, Maria Teresa Perri, Florian Heitz, Nicole Concin, Francesco Fanfani, Enrico Vizza, Giovanni Scambia, Philipp Harter, Anna Fagotti
Summary: This study aimed to assess the disease-free survival and overall survival of patients with grade 1-2 endometrioid ovarian carcinoma according to surgical staging. The results showed that lymphadenectomy and younger age were independent protective factors for survival. Patients undergoing lymphadenectomy had better survival rates.
EUROPEAN JOURNAL OF CANCER
(2023)
Article
Oncology
Fabrizio Nelli, Antonella Virtuoso, Diana Giannarelli, Agnese Fabbri, Julio Rodrigo Giron Berrios, Eleonora Marrucci, Cristina Fiore, Enzo Maria Ruggeri
Summary: This study evaluates the impact of concomitant use of acetaminophen (APAP) on the efficacy of PD-1/PD-L1 inhibitors in advanced non-small cell lung cancer (NSCLC) patients. The findings strengthen the available evidence that concurrent intake of APAP blunts the efficacy of immune checkpoint inhibitors (ICIs) in patients with advanced NSCLC, with the detrimental effects depending on the cumulative dose and duration of exposure to APAP.
Article
Oncology
Luisa Carbognin, Cristina Accetta, Danilo Di Giorgio, Paola Fuso, Margherita Muratore, Giordana Tiberi, Francesco Pavese, Tatiana D'Angelo, Alessandra Fabi, Diana Giannarelli, Alba Di Leone, Stefano Magno, Giorgia Garganese, Alejandro Martin Sanchez, Daniela Andreina Terribile, Gianluca Franceschini, Riccardo Masetti, Giovanni Scambia, Ida Paris
Summary: This study evaluated the efficacy and safety of a scalp cooling device in preventing chemotherapy-induced alopecia in breast cancer patients. The results demonstrated that the scalp cooling device was effective in preventing hair loss and had a low rate of adverse events.